MPR1d
Week 52 Data Show Inebilizumab Continues to Benefit in AChR+ Myasthenia Gravis
Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.
Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year
Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...
Clinical Trials Arena on MSN1d
Amgen’s gMG therapy cuts disease symptoms at one-year mark
Amgen’s Uplizna (inebilizumab-cdon) has shown sustained efficacy in a group of gMG patients after 52 weeks in a Phase III ...
Amgen reports new data from Phase 3 registrational MINT trial of Uplinza
Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with ...